HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Plata, F. Articles by Engers, H. D. Search for Related Content PubMed Articles by Plata, F. Articles by Engers, H. D.

Characterization of Effector Lymphocytes Associated with Immunity to Murine Sarcoma Virus (MSV) Induced Tumors

I. Physical Properties of Cytolytic T Lymphocytes Generated in Vitro and of Their Immediate Progenitors¹

From the Unit of Human Cancer Immunology, Lausanne Branch, Ludwig Institute for Cancer Research, and Department of Immunology, Swiss Institute for Experimental Cancer Research, 1011 Lausanne, Switzerland

Abstract

Cytolytic T lymphocytes (CTL) were generated in secondary mixed leukocyte-tumor cell cultures (MLTC) with syngeneic RB1-5 tumor cells as stimulating cells and with responding spleen cells from regressor mice that had rejected a murine sarcoma virus (MSV)-induced tumor. CTL precursor cells were found to be exclusively of thymic origin and non-T cells were apparently not required for CTL generation. When the size variations of CTL from syngeneic MLTC were analyzed by velocity sedimentation it appeared that a transition from small precursor cells to larger effector cells occurred during the first 5 days in culture; this change in cell size was then followed by a shift toward small-sized cells. Furthermore, the CTL generated in syngeneic MLTC in the MSV tumor immune system were compared with those CTL obtained in allogeneic mixed leukocyte cultures (MLC) and were shown to exhibit fundamental similarities.

Footnotes

¹ This investigation was supported in part by grants from the Swiss National Foundation for Scientific Research.

² Chargé de Recherches at Institut National de la Santé et de la Recherche Médicale, France. Present address: Laboratoire d'Immunologie des Tumeurs, Bâtiment Gustave Roussy, Hôpital Cochin, 75014 Paris, France.

³ Supported by a Postdoctoral Fellowship from the Medical Research Council of Canada. Present address: The Ontario Cancer Foundation, London, Canada.

⁴ To whom reprint requests should be sent.